AZ And Merck Notch Another Win For Koselugo In Adults With NF1
The MEK inhibitor, already approved for pediatric patients with the rare condition neurofibromatosis type 1, showed benefits for adults in a Phase III trial.
The MEK inhibitor, already approved for pediatric patients with the rare condition neurofibromatosis type 1, showed benefits for adults in a Phase III trial.